{rfName}

Indexed in

License and use

Citations

1

Altmetrics

Grant support

This work was partly supported by the grants PID2021-122116OB-I00 (M.V.-C. and X.P.) , funded by MICIU/AEI/10.13039/501100011033 and "ERDF, A Way of Making Europe", the "Fundacio La Marato de TV3" to M.V-C, and FIS PI21/00084 (Carlos III Health Institute) (J.F.N.) . CIBER in Diabetes and Associated Metabolic Diseases (CIBERDEM) , CIBER of Rare Diseases (CIBERER) , and CIBER in Cardiovascular Diseases (CIBERCV) are Carlos III Health Institute projects. Support was also received from the CERCA Programme/Generalitat.

Analysis of institutional authors

Valenzuela-Alcaraz, BrendaAuthorCrispi, FatimaAuthor

Share

Publications
>
Article

PPARβ/δ prevents inflammation and fibrosis during diabetic cardiomyopathy

Publicated to:Pharmacological Research. 210 107515- - 2024-12-01 210(), DOI: 10.1016/j.phrs.2024.107515

Authors: Rostami, Adel; Palomer, Xavier; Pizarro-Delgado, Javier; Barroso, Emma; Valenzuela-Alcaraz, Brenda; Crispi, Fatima; Nistal, J Francisco; Hurle, Maria A; Garcia, Raquel; Wahli, Walter; Vazquez-Carrera, Manuel

Affiliations

Hosp St Joan de Deu, Dept Oncol, Barcelona 08950, Spain - Author
INRAE, Res Ctr Food Toxicol, Toxalim, UMR1331, F-31300 Toulouse, France - Author
Inst Salud Carlos III, Spanish Biomed Res Ctr Cardiovasc Dis CIBERCV, Santander, Spain - Author
Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 308232, Singapore - Author
Spanish Biomed Res Ctr Diabet & Associated Metab, ISCIII, Madrid 28029, Spain - Author
Spanish Biomed Res Ctr Rare Dis CIBERER, Barcelona, Spain - Author
Univ Barcelona, Fac Pharm & Food Sci, Dept Pharmacol Toxicol & Therapeut Chem, Barcelona 08028, Spain - Author
Univ Barcelona, Hosp St Joan Deu, Inst Invest Biomed August Pi & Sunyer, BCNatal, Barcelona, Spain - Author
Univ Barcelona, Inst Biomed, IBUB, Barcelona 08028, Spain - Author
Univ Cantabria, Dept Fisiol & Farmacol, Fac Med, Inst Invest Marques De Valdecilla IDIVAL, E-39011 Santander, Spain - Author
Univ Cantabria, Inst Invest Marques De Valdecilla IDIVAL, Dept Ciencias Med & Quirurg, Serv Cirugia Cardiovasc,Fac Med,Hosp Univ Marques, Santander, Spain - Author
Univ Lausanne, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland - Author
See more

Abstract

Diabetic cardiomyopathy (DCM) is a specific type of myocardial disease that often develops in patients suffering from diabetes, which has become the foremost cause of death among them. It is an insidious multifactorial disease caused by complex and partially unknown mechanisms that include metabolic dysregulation, local inflammation, fibrosis, and cardiomyocyte apoptosis. Despite its severity and poor prognosis, it often goes undiagnosed, and there are currently no approved specific drugs to prevent or even treat it. Peroxisome proliferator-activated receptor (PPAR)beta/delta is a key metabolic regulator that has been proposed as a potential

Keywords

(4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)acetic acidActivationActivator protein-1 (ap-1)AnimalsCardiac fibrosisCell lineDiabetes mellitus, experimentalDiabetic cardiomyopathiesDiabetic cardiomyopathyEndoplasmic-reticulum stressExpressionFibrosisGeneHeart-failureHumansHypertrophInflammationMaleMiceMice, inbred c57blMice, knockoutMitogen-activated protein kinases (mapk)Myocytes, cardiacNuclear factor kappa b (nf-kappa b)Nuclear factor κb (nf-κb)Oxidative stressPeroxisome proliferator-activated receptoPeroxisome proliferator-activated receptor (ppar)β/δPhenolsPpar deltaPpar-betaProliferationReceptorSulfhydryl compoundsThiazoles

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Pharmacological Research due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 13/354, thus managing to position itself as a Q1 (Primer Cuartil), in the category Pharmacology & Pharmacy. Notably, the journal is positioned above the 90th percentile.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-06-27:

  • Scopus: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-27:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 12.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 12 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 72.91.
  • The number of mentions on the social network X (formerly Twitter): 4 (Altmetric).
  • The number of mentions in news outlets: 10 (Altmetric).

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: France; Singapore; Switzerland.